- Home
- GDRX vs SLS Comparison
GDRX vs SLS Comparison
Compare GDRX & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDRX | SLS |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.9M | 706.7M |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | GDRX | SLS |
|---|---|---|
| Price | $1.96 | $4.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | $3.86 | ★ $10.00 |
| AVG Volume (30 Days) | 3.1M | ★ 6.6M |
| Earning Date | 05-06-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | 50.00 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $796,853,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.38 | $67.40 |
| P/E Ratio | $22.67 | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.77 | $0.95 |
| 52 Week High | $5.61 | $6.14 |
Technical Indicators
Market Signals| Indicator | GDRX | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 38.01 | 43.93 |
| Support Level | $1.77 | $3.35 |
| Resistance Level | $2.47 | $5.01 |
| Average True Range (ATR) | 0.08 | 0.49 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 2.00 | 0.32 |
Price Performance
Historical ComparisonAbout GDRX GoodRx Holdings Inc.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.